Earnings Preview: What To Expect From Vertex Pharmaceuticals' Report

Company Overview - Vertex Pharmaceuticals Incorporated (VRTX) has a market cap of $104.6 billion and focuses on developing therapies for serious diseases, primarily cystic fibrosis (CF) [1] - The company is also working on treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, and other conditions [1] Financial Performance - Vertex is expected to announce its fiscal Q3 2025 results on November 3, with analysts predicting an adjusted EPS of $3.98, a decrease of 1.5% from $4.04 in the same quarter last year [2] - For fiscal 2025, analysts forecast an adjusted EPS of $15.84, a significant increase from a loss of $1.35 per share in fiscal 2024 [3] Stock Performance - Over the past 52 weeks, Vertex's shares have declined by 15.6%, underperforming the S&P 500 Index, which increased by 13.9%, and the Health Care Select Sector SPDR Fund, which saw a decline of 6.8% [4] - Following the announcement of better-than-expected Q2 2025 results, including an adjusted EPS of $4.52 and revenue of $2.96 billion, Vertex's shares fell by 20.6% due to the halt of its non-opioid painkiller VX-993 development after a failed trial [5] Analyst Ratings - The consensus rating for VRTX stock is "Moderate Buy," with 18 out of 33 analysts recommending a "Strong Buy," one a "Moderate Buy," 13 a "Hold," and one a "Strong Sell" [6] - The average analyst price target for Vertex Pharmaceuticals is $491.52, suggesting a potential upside of 19.9% from current levels [6]